The ELISA-Measured Increase in Cerebrospinal Fluid Tau that Discriminates Alzheimer's Disease from other Neurodegenerative Disorders is not Attributable to Differential Recognition of Tau Assembly Forms
(2013) In Journal of Alzheimer's Disease 33(4). p.923-928- Abstract
- Elevated cerebrospinal fluid concentrations of tau discriminate Alzheimer's disease from other neurodegenerative conditions. The reasons for this are unclear. While commercial assay kits are widely used to determine total-tau concentrations, little is known about their ability to detect different aggregation states of tau. We demonstrate that the leading commercial enzyme-linked immunosorbent assay reliably detects aggregated and monomeric tau and evinces good recovery of both species when added into cerebrospinal fluid. Hence, the disparity between total-tau levels encountered in Alzheimer's disease and other neurodegenerative conditions is not due to differential recognition of tau assembly forms or the extent of degeneration.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8511178
- author
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- OLIGOMERS, PROTEIN, DEMENTIA, CSF BIOMARKERS, RESEARCH CRITERIA, CLINICAL-DIAGNOSIS, PARKINSONS-DISEASE, CORTICOBASAL DEGENERATION, FRONTOTEMPORAL LOBAR DEGENERATION, PROGRESSIVE SUPRANUCLEAR PALSY
- in
- Journal of Alzheimer's Disease
- volume
- 33
- issue
- 4
- pages
- 923 - 928
- publisher
- IOS Press
- external identifiers
-
- scopus:84873645714
- pmid:23034520
- ISSN
- 1387-2877
- DOI
- 10.3233/JAD-2012-121393
- project
- Endocrine and diagnostic aspects of cognitive impairment
- language
- English
- LU publication?
- no
- id
- 630d9504-51b6-48c8-9d43-ffa65f8d7357 (old id 8511178)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23034520
- date added to LUP
- 2016-04-04 07:50:34
- date last changed
- 2022-04-07 23:13:19
@article{630d9504-51b6-48c8-9d43-ffa65f8d7357, abstract = {{Elevated cerebrospinal fluid concentrations of tau discriminate Alzheimer's disease from other neurodegenerative conditions. The reasons for this are unclear. While commercial assay kits are widely used to determine total-tau concentrations, little is known about their ability to detect different aggregation states of tau. We demonstrate that the leading commercial enzyme-linked immunosorbent assay reliably detects aggregated and monomeric tau and evinces good recovery of both species when added into cerebrospinal fluid. Hence, the disparity between total-tau levels encountered in Alzheimer's disease and other neurodegenerative conditions is not due to differential recognition of tau assembly forms or the extent of degeneration.}}, author = {{O'Dowd, S. T. and Ardah, M. T. and Johansson, Per and Lomakin, A. and Benedek, G. B. and Roberts, K. A. and Cummins, G. and El Agnaf, O. M. and Svensson, J. and Zetterberg, H. and Lynch, T. and Walsh, D. M.}}, issn = {{1387-2877}}, keywords = {{OLIGOMERS; PROTEIN; DEMENTIA; CSF BIOMARKERS; RESEARCH CRITERIA; CLINICAL-DIAGNOSIS; PARKINSONS-DISEASE; CORTICOBASAL DEGENERATION; FRONTOTEMPORAL LOBAR DEGENERATION; PROGRESSIVE SUPRANUCLEAR PALSY}}, language = {{eng}}, number = {{4}}, pages = {{923--928}}, publisher = {{IOS Press}}, series = {{Journal of Alzheimer's Disease}}, title = {{The ELISA-Measured Increase in Cerebrospinal Fluid Tau that Discriminates Alzheimer's Disease from other Neurodegenerative Disorders is not Attributable to Differential Recognition of Tau Assembly Forms}}, url = {{http://dx.doi.org/10.3233/JAD-2012-121393}}, doi = {{10.3233/JAD-2012-121393}}, volume = {{33}}, year = {{2013}}, }